IPP Bureau

AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients
AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients

By IPP Bureau - November 21, 2025

The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study

BPL Medical Technologies brings next-gen Korean ultrasound to India
BPL Medical Technologies brings next-gen Korean ultrasound to India

By IPP Bureau - November 21, 2025

The X CUBE 50 integrates ALPINION’s advanced X+ Architecture

Healthium Medtech to invest Rs. 150 crore in new Sri City facility, create 400 jobs
Healthium Medtech to invest Rs. 150 crore in new Sri City facility, create 400 jobs

By IPP Bureau - November 21, 2025

Merck’s two-drug HIV regimen hits phase 3 success
Merck’s two-drug HIV regimen hits phase 3 success

By IPP Bureau - November 21, 2025

The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks

Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment
Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment

By IPP Bureau - November 21, 2025

This is the first and only subcutaneous immune checkpoint inhibitor available in Europe

GSK and Fleming Initiative launch bold new fight against antimicrobial resistance
GSK and Fleming Initiative launch bold new fight against antimicrobial resistance

By IPP Bureau - November 21, 2025

These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections

GSK teams up with LTZ Therapeutics to launch next-generation cancer therapies
GSK teams up with LTZ Therapeutics to launch next-generation cancer therapies

By IPP Bureau - November 21, 2025

The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy

Merck KGaA fires up new supercomputer to turbocharge scientific breakthroughs
Merck KGaA fires up new supercomputer to turbocharge scientific breakthroughs

By IPP Bureau - November 21, 2025

Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure

Alkem launches globally acclaimed De Simone Probiotic in India, expands GI portfolio
Alkem launches globally acclaimed De Simone Probiotic in India, expands GI portfolio

By IPP Bureau - November 21, 2025

The formulation is backed by over 80 clinical trials and 200 scientific publications

Mankind Pharma inks licencing pact with Actimed to bring cachexia treatments to South Asia
Mankind Pharma inks licencing pact with Actimed to bring cachexia treatments to South Asia

By IPP Bureau - November 21, 2025

The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands

Kiran Mazumdar-Shaw ranked 2nd most generous woman by Hurun India
Kiran Mazumdar-Shaw ranked 2nd most generous woman by Hurun India

By IPP Bureau - November 21, 2025

The 2025 edition of the EdelGive Hurun list recognizes 24 exceptional women leaders for their philanthropic impact across critical areas

SOMA and Aura partner to advance innovation in on-press color correction
SOMA and Aura partner to advance innovation in on-press color correction

By IPP Bureau - November 21, 2025

SOMA Color Mind is designed to simplify and accelerate color setup directly on the printing press

Piramal Pharma Solutions’ UK facility bags updated MHRA GMP certification
Piramal Pharma Solutions’ UK facility bags updated MHRA GMP certification

By IPP Bureau - November 21, 2025

Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub

Innovent Biologics’ experimental weight-loss drug achieves breakthrough in Phase 3 trial
Innovent Biologics’ experimental weight-loss drug achieves breakthrough in Phase 3 trial

By IPP Bureau - November 21, 2025

Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration

Siolta Therapeutics’ novel microbiome therapy shows promise in preventing allergic diseases in infants
Siolta Therapeutics’ novel microbiome therapy shows promise in preventing allergic diseases in infants

By IPP Bureau - November 21, 2025

Latest Stories

Interviews

Packaging